1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Regulation

Coloplast Vaginal Mesh Postmarket Data Shows Similar Safety To Native Tissue Repair

 
• By Elizabeth Orr

The company’s review of patient safety data found similar adverse event rates between patients treated with transvaginal mesh and those treated surgically. However, the FDA still says the benefits of the treatment do not outweigh its risks

3D illustration of the number 522 against a maroon background.
• Source: Shutterstock

Women who were treated for pelvic organ prolapse (POP) using Coloplast Ltd. transvaginal mesh experienced similar outcomes at 36 months to those treated with native tissue repair, the US Food and Drug Administration said on 17 October.

The data came from a

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation